A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
about
Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicNew strategies in the treatment of multiple myeloma.Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cellsA multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patientsProfile of elotuzumab and its potential in the treatment of multiple myelomaNaïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironmentMyeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaImmunotherapy for multiple myeloma.T cell-based targeted immunotherapies for patients with multiple myeloma.Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.Is immunotherapy here to stay in multiple myeloma?Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myelomaDendritic cell cancer vaccines: from the bench to the bedside.Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.Signaling lymphocytic activation molecules Slam and cancers: friends or foes?
P2860
Q27023621-411FB3ED-E1BA-4115-8B4E-DC172109A4ABQ33958520-DC513691-D1EA-4644-A4FE-F9A184EA9975Q33992425-863C0D53-E3D8-4E54-9B3B-F353B7E7C19CQ34543937-CEA2DAF6-D353-455C-A298-9773210B7B6BQ35628678-E69DD7A2-CC0B-4C04-B02B-E7D2BA5AD33EQ37010531-A965FC7B-1A32-484D-B69F-54B8DD9BCEA4Q37340304-F8432FF4-E887-4A46-8DFC-58E7C941D24CQ37666309-320E4203-3713-466E-ABA5-A4666F59C417Q38177879-27782CD4-B53F-4ED4-8FEB-CFEE8A1AC344Q38246639-BAAF141C-DBE0-42F8-859D-C20582B4B9E8Q38580545-5BCB6026-1D49-47C7-BE1F-C7D0E5DACA93Q38809499-BCD05FEB-6B2F-404A-BD9D-AFA987E2DEA7Q39084427-29DCEC3B-2B6C-4705-AEA8-8FD6ABE1B32EQ39389614-BB7353F1-BD5B-4734-B227-43F54ACE340AQ42287234-4C7ED59A-EC45-4518-8FE9-D313D01A6E99Q42979673-10E8B721-DDE4-412B-BD82-10725B8950E0Q47580433-B915C808-C10F-41D0-8447-EB27CF0140ACQ52584346-51A2CF04-6BB3-4997-ADDD-00B333BBDD54
P2860
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 April 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel immunogenic CS1-specif ...... es targeting multiple myeloma.
@en
A novel immunogenic CS1-specif ...... es targeting multiple myeloma.
@nl
type
label
A novel immunogenic CS1-specif ...... es targeting multiple myeloma.
@en
A novel immunogenic CS1-specif ...... es targeting multiple myeloma.
@nl
prefLabel
A novel immunogenic CS1-specif ...... es targeting multiple myeloma.
@en
A novel immunogenic CS1-specif ...... es targeting multiple myeloma.
@nl
P2093
P2860
P1476
A novel immunogenic CS1-specif ...... es targeting multiple myeloma.
@en
P2093
John Daley
Jooeun Bae
Nikhil C Munshi
Robert Smith
Weihua Song
Yu-Tzu Tai
P2860
P304
P356
10.1111/J.1365-2141.2012.09111.X
P407
P577
2012-04-26T00:00:00Z